Articles On Pharmaxis (ASX:PXS)

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s rare blood cancer program gathers pace Actinogen says 25 patients have been treated in its 200-candidate Alzheimer’s disease study   Quart...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

In drug development there’s a narrow window to get to market and long delays tend to be fatal – and not just for the patients. Ten years ago, Pharmaxis was confident of US Food and Drug Administration approval for its cystic fibrosis treatm...

Momentum trading involves buying a stock that has shown a significant movement in price or volume. One of the main benefits of momentum trading is that it can generate high returns in a short period of time, especially in volatile markets....

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

Significant changes for Pharmaxis (ASX:PXS) with the company announcing a new name and the sale of the mannitol respiratory business.

Benchmark index falls on Monday, closing out the day down 0.21% Utilities and Materials sectors edge higher, but Health Care anchors the benchmark into the red Small caps led by Galileo Mining, Infinity and last week’s rockstar Biotron...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark slides throughout the day after a shocker on Wall Street last night. Utilities did best but still ended up losing, down 0.3% for the day. Paincheck a ray of sunshine this afternoon, up 33% today despite an early speeding ticket....

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Clinical stage drug development company Pharmaxis (ASX:PXS) has announced the publication in the journal Nature Cancer of preclinical results showing pan-Lysyl Oxidase inhibitor PXS-5505 increases survival by 35 per cent compared to...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AKE)) - Allkem ((ALU)) - Altium ((AWC)) - Alumina Ltd ((ARB)) - ARB Corp ((AUB)) - AUB Group ((ACL)) - Australian Clinical Labs ((BHP)) - BHP Group ((COL)) - Coles Group...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

ASX health stocks fall in  past five days with Power noting larger names trading on attractive valuations  Neuren Pharmaceuticals has expanded its current licensing agreement with Acadia Pharmaceuticals Pharmaxis reports positive results f...

Pharmaxis (ASX:PXS) has announced details of a final interim analysis of data from ten patients who have completed six months treatment with PXS-5505.

Pharmaxis (PXS) releases the final set of interim data from its phase two cancer trial, revealing “excellent” results Ten patients with bone marrow cancer, myelofibrosis, completed six months of treatment with PXS-5505 Sixty per cent...

Little Green Pharma awarded commercial tender by French government Pharmaxis says its bone marrow cancer drug is effective   Cannabis company Little Green Pharma (ASX:LGP) has been awarded a commercial tender to supply up to $1.6 million...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm...

Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment for scarring has met its primary safety objective and two secondary biomarker endpoints in patients with established scars.

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Further testing of a potentially breakthrough scar treatment is in the works after UWA researchers found the Pharmaxis-piloted topical topical cream to be safe for human application.

ASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over the shop but came out on top with +1.2%. Wildcat (ASX:WC8) was King of the Small Caps, adding 34.5% on no fresh news.   After sinking as low...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

A handful of ASX biotechs are entering their crucial stages of development Promising outlooks for PharmAxis, Botanix Pharma, and Paragon Care   Pharmaxis could surge if FDA application successful Broker Taylor Collison sees an Outperform...

Dr Boreham’s Crucible: Radiopharm Theronostics By Tim Boreham ASX code: ((RAD)); NASDAQ code (proposed): RADX Share price: 14.5 cents Market cap: $49.15 million Shares on issue: 238,947,639 (100,000,000 more in ASX escrow) Chief executive o...

Pharmaxis CEO Gary Phillips said, “The agreement with the FDA to expand the patient population in the ongoing Phase 2 study to include those patients currently on a JAK inhibitor is an important step forward in realising the benefit...

Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2   Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm...

ASX health stocks fall 0.9% in the past five days Healius receives a $1.52 billion takeover offer from Australian Clinical Labs Pharmaceutical wholesaler Sigma reports improved performance for the financial year Healthcare and life scien...

Saturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jon Pilcher was despondent as he awaited news from the company’s US partner Acadia on whether the US Food and Drug Administration (FDA) had ap...

The ASX 200 was up 0.39% and ASX XEC slips 0.42% 10 out of 11 sectors were higher lead by Communications The Real Estate sector was the only one in the red   The ASX 200 was up 0.39% today and the ASX XEC was down 0.42%.  A total of 10 ou...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Pharmaxis (ASX:PXS) has announced the appointment of experienced senior global biopharmaceutical executive Dr Simon Green to its board as an independent non-executive director.

Warrego Energy puts out initial substantial shareholder notice for Gina Rinehart entities following takeover bid Whitehaven Coal finishes November with a new substantial shareholder as two of its directors sell down holdings Neuren Pharma...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Tom Boreham notes small caps with cash on the balance sheet are the safer bet compared to ‘pre-revenue’ companies, and highlights several examples. -‘Pre revenue’ plays without enough cash will wither away-Capital raised pre rate hikes a be...